OCPD
MCID: OBS003
MIFTS: 42

Obsessive-Compulsive Personality Disorder (OCPD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Personality Disorder

MalaCards integrated aliases for Obsessive-Compulsive Personality Disorder:

Name: Obsessive-Compulsive Personality Disorder 12 75 15
Obsessive-Compulsive Personality 55 72
Anankastic Personality Disorder 12 33
Compulsive Personality Disorder 44 72
Obsessional Personality Disorder 72
Obsessional Personality 12
Ocpd 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10932
ICD9CM 35 301.4
MeSH 44 D003193
NCIt 50 C92638
SNOMED-CT 68 1376001
ICD10 33 F60.5
UMLS 72 C0009595 C1704373 C3714689

Summaries for Obsessive-Compulsive Personality Disorder

Disease Ontology : 12 A personality disorder that is characterized by a pervasive pattern of preoccupation with orderliness, perfectionism, and mental and interpersonal control at the expense of flexibility, openness, and efficiency.

MalaCards based summary : Obsessive-Compulsive Personality Disorder, also known as obsessive-compulsive personality, is related to obsessive-compulsive disorder and disease of mental health. An important gene associated with Obsessive-Compulsive Personality Disorder is DRD3 (Dopamine Receptor D3). The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are Decreased DCP1a protein expression and assembly in processing bodies after arsenite stimulation and behavior/neurological

Wikipedia : 75 Obsessive-compulsive personality disorder (OCPD) is a personality disorder characterized by a general... more...

Related Diseases for Obsessive-Compulsive Personality Disorder

Diseases related to Obsessive-Compulsive Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Related Disease Score Top Affiliating Genes
1 obsessive-compulsive disorder 31.0 SLC6A4 DRD3
2 disease of mental health 30.2 SLC6A4 DRD3
3 mood disorder 30.2 SLC6A4 DRD3
4 personality disorder 11.1
5 avoidant personality disorder 11.0
6 severe combined immunodeficiency 10.6
7 major depressive disorder 10.6
8 mental depression 10.6
9 depression 10.6
10 anxiety 10.5
11 borderline personality disorder 10.5
12 eating disorder 10.5
13 anorexia nervosa 10.5
14 panic disorder 10.5
15 supranuclear palsy, progressive, 1 10.4
16 attention deficit-hyperactivity disorder 10.3
17 schizotypal personality disorder 10.3
18 hypochondriasis 10.3
19 asperger syndrome 10.2
20 ehlers-danlos syndrome, hypermobility type 10.1
21 gilles de la tourette syndrome 10.1
22 multiple system atrophy 1 10.1
23 autism 10.1
24 bulimia nervosa 10.1
25 autism spectrum disorder 10.1
26 paraphilia disorder 10.1
27 separation anxiety disorder 10.1
28 social phobia 10.1
29 intermittent explosive disorder 10.1
30 ehlers-danlos syndrome 10.1
31 hypermobility syndrome 10.1
32 generalized anxiety disorder 10.1
33 epilepsy 10.1
34 tic disorder 10.1
35 temporal lobe epilepsy 10.1
36 histrionic personality disorder 10.1
37 essential tremor 10.1
38 hypermobile ehlers-danlos syndrome 10.1
39 periodontal ehlers-danlos syndrome 10.1
40 tremor 10.1
41 pathological gambling 10.1 SLC6A4 DRD3
42 migraine without aura 10.1 SLC6A4 DRD3
43 alcohol dependence 10.1
44 opiate dependence 10.1 SLC6A4 DRD3
45 cocaine dependence 10.1 SLC6A4 DRD3
46 drug dependence 10.1 SLC6A4 DRD3
47 substance abuse 10.1 SLC6A4 DRD3
48 phobic disorder 10.1 SLC6A4 PIR
49 schizoaffective disorder 10.0 SLC6A4 DRD3
50 dysthymic disorder 10.0 SLC6A4 PIR

Comorbidity relations with Obsessive-Compulsive Personality Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Personality Disorder:



Diseases related to Obsessive-Compulsive Personality Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Personality Disorder

GenomeRNAi Phenotypes related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased DCP1a protein expression and assembly in processing bodies after arsenite stimulation GR00203-A 8.62 DRD3 SLC6A4

MGI Mouse Phenotypes related to Obsessive-Compulsive Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.55 CLPS DRD3 IDS SLC6A4 TMEM79
2 growth/size/body region MP:0005378 9.43 CLPS DRD3 IDS PIR SLC6A4 TMEM79
3 integument MP:0010771 8.92 CLPS IDS SLC6A4 TMEM79

Drugs & Therapeutics for Obsessive-Compulsive Personality Disorder

Drugs for Obsessive-Compulsive Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Norepinephrine Approved Phase 4 51-41-2 439260
6
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
13
Cycloserine Approved Phase 4 68-41-7 6234 401
14
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
17
Sertraline Approved Phase 4 79617-96-2 68617
18
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
19
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
20
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
21 Central Nervous System Depressants Phase 4
22 Quetiapine Fumarate Phase 4 111974-72-2
23 Antipsychotic Agents Phase 4
24 Antidepressive Agents, Tricyclic Phase 4
25 Dopamine Antagonists Phase 4
26 Dopamine Agents Phase 4
27 Hormones Phase 4
28 Calcium, Dietary Phase 4
29 calcium channel blockers Phase 4
30 Central Nervous System Stimulants Phase 4
31 Dopamine Uptake Inhibitors Phase 4
32 Parasympatholytics Phase 4
33 Cholinergic Agents Phase 4
34 Muscarinic Antagonists Phase 4
35 Cholinergic Antagonists Phase 4
36 Antiparkinson Agents Phase 4
37 Hypoglycemic Agents Phase 4
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
39 Duloxetine Hydrochloride Phase 4
40 Tryptophan Phase 4
41 Haloperidol decanoate Phase 4
42 Serotonin Receptor Agonists Phase 4
43 Acidophilus Phase 4
44 Antimalarials Phase 4
45 Antiparasitic Agents Phase 4
46 Sulfalene Phase 4
47 Antiprotozoal Agents Phase 4
48 Bifidobacterium Phase 4
49 Anti-Bacterial Agents Phase 4
50 Anti-Infective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 357)
# Name Status NCT ID Phase Drugs
1 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Unknown status NCT00182520 Phase 4 Topiramate;placebo
2 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
3 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
4 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
5 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
6 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
7 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
8 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
9 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
10 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
11 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
12 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
13 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
14 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
15 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
16 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
17 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
18 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
19 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
20 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
21 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
22 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
23 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
24 Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
25 Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD Recruiting NCT03993535 Phase 4 selective serotonin reuptake inhibitor
26 A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder Recruiting NCT02334644 Phase 4
27 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
28 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Not yet recruiting NCT04015596 Phase 4 Naproxen Sodium
29 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
30 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
31 SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
32 A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
33 Pharmacogenetics in Primary Care Psychotropics Unknown status NCT03232502 Phase 3
34 Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder Unknown status NCT02375152 Phase 2, Phase 3
35 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study Unknown status NCT02590445 Phase 2, Phase 3
36 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
37 Family Based Treatment of Early Childhood OCD Completed NCT00055068 Phase 3
38 Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder. Completed NCT01807403 Phase 3
39 A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy Completed NCT00182000 Phase 3 seromycin
40 A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
41 A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects Completed NCT02229903 Phase 3
42 Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study Completed NCT00000389 Phase 3 Fluvoxamine
43 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
44 Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial Completed NCT00674219 Phase 3 Memantine
45 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
46 Treatment of Pediatric OCD for SRI Partial Responders Completed NCT00074815 Phase 3 Serotonin reuptake inhibitors management
47 Behavior Therapy for Childhood OCD Completed NCT00000386 Phase 3
48 Treatment of Pediatric Obsessive-Compulsive Disorder Completed NCT00000384 Phase 3 Sertraline
49 Family Based Treatment for Early Childhood OCD Completed NCT00533806 Phase 3
50 1/2 D-cycloserine Augmentation of CBT for Pediatric OCD Completed NCT01411774 Phase 3 d-cycloserine;Pill placebo

Search NIH Clinical Center for Obsessive-Compulsive Personality Disorder

Cochrane evidence based reviews: compulsive personality disorder

Genetic Tests for Obsessive-Compulsive Personality Disorder

Anatomical Context for Obsessive-Compulsive Personality Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Personality Disorder:

41
Brain, Testes, Cortex, Subthalamic Nucleus, Skin, Caudate Nucleus, Thalamus

Publications for Obsessive-Compulsive Personality Disorder

Articles related to Obsessive-Compulsive Personality Disorder:

(show top 50) (show all 430)
# Title Authors PMID Year
1
Obsessive compulsive personality traits: Understanding the chain of pathogenesis from health to disease. 38
31202047 2019
2
Obsessive-compulsive personality disorder symptoms as a risk factor for postpartum depressive symptoms. 38
30171361 2019
3
Editorial: Hoarding and Obsessive-Compulsive Disorder. 38
31108161 2019
4
Overlap of obsessive-compulsive personality disorder and autism spectrum disorder traits among OCD outpatients: an exploratory study. 38
31375037 2019
5
Personality disorder traits in young adults with subclinical obsessive-compulsive symptoms: Not just traits related to obsessive-compulsive personality. 38
31380698 2019
6
Homicidal Ideation and Forensic Psychopathology: Evidence From the 2016 Nationwide Emergency Department Sample (NEDS). 38
31404481 2019
7
Hippocampus and amygdalar volumes in patients with obsessive-compulsive personality disorder. 38
30962058 2019
8
Volumetric MRI study of orbito-frontal cortex and thalamus in obsessive-compulsive personality disorder. 38
30962057 2019
9
Psychopathological and psychiatric evaluation of patients affected by lipodystrophy. 38
31144218 2019
10
A Psychometric Examination of the Pathological Obsessive Compulsive Personality Scale (POPS): Initial Study in an Undergraduate Sample. 38
29494778 2019
11
Crossed obsessive-compulsive personality disorder and impaired theory of mind in temporal lobe epilepsy. 38
30554354 2019
12
An epidemiological survey of psychiatric disorders in Iran: Kermanshah. 38
31096141 2019
13
Association between cognitive impairments and obsessive-compulsive spectrum presentations following traumatic brain injury. 38
28043199 2019
14
Is problematic exercise really problematic? A dimensional approach. 38
30915933 2019
15
[Attention-deficit/hyperactivity disorder (ADHD) in adult psychiatry: Data on 12-month prevalence, risk factors and comorbidity]. 38
29490380 2019
16
The concurrent validity of a Web-based self-report assessment for personality disorders. 38
30592174 2019
17
Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder. 38
30353921 2019
18
Psychological impact of fibromyalgia: current perspectives. 38
30858740 2019
19
The role of personality disorders in obsessive-compulsive disorder. 38
30745684 2019
20
Problematic overstudying: Studyholism or study addiction? 38
30541335 2018
21
Prevalence of personality disorders in the general adult population in Western countries: systematic review and meta-analysis. 38
30261937 2018
22
Obsessive, compulsive, and conscientious? The relationship between OCPD and personality traits. 38
29272027 2018
23
[The psychiatric comorbidity of anorexia nervosa: A comparative study in a population of French and Greek anorexic patients]. 38
29102367 2018
24
The relationship between obsessive compulsive personality and obsessive compulsive disorder treatment outcomes: Predictive utility and clinically significant change - CORRIGENDUM. 38
29615137 2018
25
Recovery and Nonrecovery After Psychotherapy With Transference Interpretation: Two Case Studies. 38
30049221 2018
26
Examining the DSM-5 alternative model of personality disorders operationalization of obsessive-compulsive personality disorder in a mental health sample. 38
29927297 2018
27
Psychic euosmia and obsessive compulsive personality disorder. 38
30254981 2018
28
Gambling disorder and obsessive-compulsive personality disorder: A frequent but understudied comorbidity. 38
29936850 2018
29
Obsessive-compulsive personality disorder features and response to behavioral therapy for insomnia among patients with hypnotic-dependent insomnia. 38
29869891 2018
30
ICD-11 and DSM-5 personality trait domains capture categorical personality disorders: Finding a common ground. 38
28835108 2018
31
Psychological Factors Including Demographic Features, Mental Illnesses, and Personality Disorders as Predictors in Internet Addiction Disorder. 38
29997655 2018
32
Psychiatric (Axis I) and personality (Axis II) disorders and subjective psychiatric symptoms in chronic tinnitus. 38
29188734 2018
33
Anxiety, Mood, and Personality Disorders in Patients with Benign Paroxysmal Positional Vertigo. 38
30042641 2018
34
Stability of the Pregnancy Obsessive-Compulsive Personality Disorder Symptoms Checklist. 38
29067550 2018
35
Associations Between Personality Disorder Characteristics, Psychological Symptoms, and Sexual Functioning in Young Women. 38
29276043 2018
36
Substance-use disorders, personality traits, and sex differences in institutionalized adolescents. 38
30067395 2018
37
Development and Examination of the Five-Factor Obsessive-Compulsive Inventory-Short Form. 38
27095820 2018
38
Continuity between DSM-5 Section II and Section III personality traits for obsessive-compulsive personality disorder. 38
29024130 2018
39
Suicidality in People With Obsessive-Compulsive Symptoms or Personality Traits. 38
30692943 2018
40
The role of cerebellar impairment in emotion processing: a case study. 38
30345063 2018
41
Examining the DSM-5 Section III Criteria for Obsessive-Compulsive Personality Disorder in a Community Sample. 38
28263093 2017
42
Interpersonal problems across levels of the psychopathology hierarchy. 38
28735709 2017
43
The role of experiential avoidance in obsessive-compulsive personality disorder traits. 38
27845528 2017
44
The Relationship between Obsessive Compulsive Personality and Obsessive Compulsive Disorder Treatment Outcomes: Predictive Utility and Clinically Significant Change. 38
28390444 2017
45
Impact of obsessive-compulsive personality disorder symptoms in Internet users. 38
28738097 2017
46
Gender differences in automatic thoughts and cortisol and alpha-amylase responses to acute psychosocial stress in patients with obsessive-compulsive personality disorder. 38
28363118 2017
47
Coverage of the DSM-IV-TR/DSM-5 Section II Personality Disorders With the DSM-5 Dimensional Trait Model. 38
27617654 2017
48
Comorbidity, age of onset and suicidality in obsessive-compulsive disorder (OCD): An international collaboration. 38
28433854 2017
49
[Hyperuricemia and gene mutations: a case report]. 38
28700181 2017
50
An investigation of doubt in obsessive-compulsive disorder. 38
28359017 2017

Variations for Obsessive-Compulsive Personality Disorder

Expression for Obsessive-Compulsive Personality Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Personality Disorder.

Pathways for Obsessive-Compulsive Personality Disorder

GO Terms for Obsessive-Compulsive Personality Disorder

Biological processes related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 social behavior GO:0035176 8.96 SLC6A4 DRD3
2 digestion GO:0007586 8.62 PIR CLPS

Sources for Obsessive-Compulsive Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....